| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.73B | 4.69B | 4.60B | 4.35B | 3.78B | 2.92B |
| Gross Profit | 1.32B | 1.27B | 1.18B | 1.40B | 1.13B | 875.46M |
| EBITDA | 1.22B | 1.18B | 1.16B | 1.17B | 913.93M | 371.69M |
| Net Income | 686.17M | 644.30M | 585.09M | 581.95M | 382.78M | -148.19M |
Balance Sheet | ||||||
| Total Assets | 8.81B | 8.17B | 8.30B | 7.76B | 7.04B | 5.67B |
| Cash, Cash Equivalents and Short-Term Investments | 655.23M | 601.75M | 630.85M | 483.29M | 578.96M | 601.99M |
| Total Debt | 2.35B | 2.20B | 2.26B | 2.21B | 1.54B | 853.75M |
| Total Liabilities | 3.55B | 3.43B | 3.40B | 3.36B | 2.66B | 1.64B |
| Stockholders Equity | 5.24B | 4.72B | 4.88B | 4.38B | 4.36B | 4.01B |
Cash Flow | ||||||
| Free Cash Flow | 506.58M | 534.22M | 570.04M | 71.33M | -635.76M | 317.07M |
| Operating Cash Flow | 1.20B | 1.15B | 1.28B | 782.29M | 401.09M | 864.57M |
| Investing Cash Flow | -795.81M | -690.00M | -772.89M | -1.22B | -1.03B | -574.52M |
| Financing Cash Flow | -119.48M | -467.17M | -359.69M | 379.45M | 579.93M | -339.12M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €9.36B | 13.64 | 14.15% | 3.19% | 2.87% | 17.03% | |
74 Outperform | HK$10.11B | 8.87 | 14.64% | 9.74% | 28.34% | ― | |
65 Neutral | €6.41B | 10.31 | 7.29% | 2.70% | 11.18% | 46.57% | |
64 Neutral | HK$11.86B | 14.72 | 13.83% | 1.71% | -13.95% | -13.61% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
60 Neutral | HK$4.30B | 12.28 | 18.09% | 2.35% | -0.21% | -27.21% | |
56 Neutral | HK$6.55B | -582.50 | -0.43% | ― | 7.11% | 77.53% |
Impro Precision Industries Limited reported a robust sales performance for the third quarter of 2025, with a notable 16.8% increase in revenue compared to the previous year. The company experienced significant growth in the diversified industrials and aerospace, medical, and energy segments, driven by strong demand in AI-related and medical end-markets. Despite challenges in the global economy, the company forecasts continued sales growth for the full year, although the automotive segment saw a decline.
The most recent analyst rating on (HK:1286) stock is a Buy with a HK$5.50 price target. To see the full list of analyst forecasts on Impro Precision Industries Limited stock, see the HK:1286 Stock Forecast page.
Impro Precision Industries Limited has announced its intention to terminate its Existing Share Option Scheme, which was adopted in June 2018, and replace it with a New Share Option Scheme. This move is in response to amendments in the Stock Exchange’s Listing Rules that came into effect in January 2023. The new scheme aims to align with market practices by offering incentives to eligible participants, enhancing enterprise value, and achieving long-term objectives for the company’s growth and development. The adoption of the new scheme is subject to shareholder approval and regulatory conditions.
The most recent analyst rating on (HK:1286) stock is a Buy with a HK$5.50 price target. To see the full list of analyst forecasts on Impro Precision Industries Limited stock, see the HK:1286 Stock Forecast page.
Impro Precision Industries Limited announced that the impact of the US Additional Tariffs on its operations is less severe than initially anticipated. This is due to most US customers agreeing to absorb the tariffs and certain product codes being exempted from the tariffs. The company plans to continue monitoring the situation and implement measures to mitigate any potential impacts.
The most recent analyst rating on (HK:1286) stock is a Buy with a HK$4.50 price target. To see the full list of analyst forecasts on Impro Precision Industries Limited stock, see the HK:1286 Stock Forecast page.
Impro Precision Industries Limited announced that the United States will impose a 50% tariff on certain steel and aluminum products, affecting about 60% of the company’s exports to the US. This development poses a significant challenge to the company’s operations, as US sales account for 44.4% of its total revenue, and the tariffs exceed the company’s gross profit margin, potentially leading to a force majeure situation.